Targeting non-coding RNA H19: A potential therapeutic approach in pulmonary diseases

Abstract

Non-coding RNA is still one of the most popular fields in biology research. In recent years, people paid more attention to the roles of H19 in lung diseases, which expressed abnormally in various pathological process. Therefore, this review focus on the regulatory role of H19 in asthma, pulmonary arterial hypertension (PAH), idiopathic pulmonary fibrosis (IPF), lung injury, pneumonia, lung cancer, etc. And the potential therapeutic agents and molecular treatments of H19 are collected. The aim is to demonstrate its underlying mechanism in pulmonary diseases and to guide the basic research targeting H19 into clinical drug translation.

Long Non-Coding RNAs in Colorectal Cancer: Navigating the Intersections of Immunity, Intercellular Communication, and Therapeutic Potential

“…These lncRNAs are linked with EMT, angiogenesis, inflammation, and matrix remodeling. H19 can upregulate HMGA2 by sponging the let-7 microRNA, and lincRNA-p21 can induce EMT in response to TGF-β, augmenting the invasive and metastatic potential of cancer cells [ 70 , 71 , 72 , 73 , 74 , 75 , 76 , 78 ] ( Table 4 ).…”

LncRNA H19 improves angiogenesis in mouse pulmonary artery endothelial cells by regulating the HIF-1α/VEGF signaling pathway

“…LncRNA H19 was reported to be able to promote lung brosis by inhibiting microRNA (miRNA or miR)-140 expression in human lung broblasts, leading to enhanced extracellular matrix deposition (26). In addition, lncRNA H19 has speci c regulatory roles in airway smooth muscle cells, adult myocytes, cardiomyocytes, small cell lung cancer lines and non-small cell lung cancer lines (29)(30)(31). The study of lncRNAs' involvement in pulmonary vascular remodeling has been recently an emerging eld.…”